Published in Biotech Law Weekly, August 20th, 2004
Andrews will replace Michael F. Cola, the chairman of the board who has served as ChromaVision interim CEO since February 2004.
Cola said the search process for a new CEO was extensive and was directed by a very specific set of qualifications involving both applicable corporate experience and personal character; he added that Andrews' direct and senior experience in diverse aspects of the diagnostics industry was an important factor as the company is presently embarking on a number of new strategic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.